Computer-based drug-utilization review--risk, benefit, or boondoggle?
Computer-based drug-utilization review--risk, benefit, or boondoggle?
复制标题
基于计算机的药物利用审查——风险、益处还是无用功？
DOI：
10.1056/nejm199506153322411
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Lipton,HL
中科院分区：
文献类型：
--
作者：
Soumerai,SB;Lipton,HL
1990年10月28日，在几乎没有辩论的情况下，国会通过了《综合预算调节法》，要求各州向大约3400万医疗补助登记人提供基于索赔的药物利用审查。1、该计划的条款借鉴了1988年不幸被废除的《医疗保险灾难性覆盖法案》；规定的目标是减少潜在的不适当的药物处方和分配，加强对患者的咨询，并减少药物支出的增长。1药物利用审查是一项系统的、持续的计划，根据预定的标准和试图防止或最大限度地减少不适当的处方来解释药物使用模式。
On October 28, 1990, with little debate, Congress passed the Omnibus Budget Reconciliation Act, requiring the states to provide claims-based drug-utilization review to approximately 34 million Medicaid enrollees.1,2The provisions of the program were borrowed from the ill-fated Medicare Catastrophic Coverage Act of 1988, repealed in 1990; the stated goals were to reduce potentially inappropriate prescribing and dispensing of medications, enhance the counseling of patients, and reduce growth in expenditures for drugs.1Drug-utilization review is a structured, ongoing program that interprets patterns of drug use in relation to predetermined criteria and attempts to prevent or minimize inappropriate prescribing.3, . . .